Action of SN 28049, a new DNA binding topoisomerase II-directed antitumour drug: Comparison with doxorubicin and etoposide

Investigational New Drugs

Volumn 29, Issue 5, 2011, Pages 1102-1110

  Drummond, Catherine J ^a,b   Finlay, Graeme J ^a   Broome, Laura ^a   Marshall, Elaine S ^a   Richardson, Emma ^a   Baguley, Bruce C ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Chemotherapy; Colon; Melanoma; Mitotic catastrophe; Tetraploid; Topoisomerase

Indexed keywords

ANTINEOPLASTIC AGENT; BETA GALACTOSIDASE; CYCLIN B; CYCLIN E; DOXORUBICIN; ETOPOSIDE; GYRASE INHIBITOR; HISTONE H2AX; N [2 (DIMETHYLAMINO)ETHYL] 2,6 DIMETHYL 1 OXO 1,2 DIHYDROBENZO[B] 1,6 NAPHTHYRIDINE 4 CARBOXAMIDE; PROTEIN P53; SN 28049; UNCLASSIFIED DRUG; CYCLIN DEPENDENT KINASE INHIBITOR 1A; DNA; DNA BINDING PROTEIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE II ALPHA; FAS ANTIGEN; FAS PROTEIN, HUMAN; N (2 (DIMETHYLAMINO)ETHYL) 2,6 DIMETHYL 1 OXO 1,2 DIHYDROXYBENZO(B) 1,6 NAPHTHYRIDINE 4 CARBOXAMIDE; N-(2-(DIMETHYLAMINO)ETHYL)-2,6-DIMETHYL-1-OXO-1,2-DIHYDROXYBENZO(B)-1,6-NAPHTHYRIDINE-4-CARBOXAMIDE; NAPHTHYRIDINE DERIVATIVE; TUMOR ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; COLON CARCINOMA; CONTROLLED STUDY; DNA DAMAGE; DRUG ACTIVITY; DRUG INHIBITION; DRUG MECHANISM; DRUG STRUCTURE; ELECTROPHORESIS; FLOW CYTOMETRY; G1 PHASE CELL CYCLE CHECKPOINT; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; M PHASE CELL CYCLE CHECKPOINT; MELANOMA; MICROSCOPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; CELL STRAIN HCT116; CHEMISTRY; COMPARATIVE STUDY; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; METABOLISM; SIGNAL TRANSDUCTION; TETRAPLOIDY;

ANIMALS; ANTIGENS, CD95; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DNA; DNA DAMAGE; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; DOXORUBICIN; ETOPOSIDE; FLOW CYTOMETRY; G1 PHASE CELL CYCLE CHECKPOINTS; HCT116 CELLS; HUMANS; INHIBITORY CONCENTRATION 50; MICE; NAPHTHYRIDINES; SIGNAL TRANSDUCTION; TETRAPLOIDY; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84856074887     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-010-9473-8     Document Type: Article

References (32)

1. Arcamone F (1985) Properties of antitumor anthracyclines and new developments in their application: Cain memorial award lecture. Cancer Res 45:5995-5999
2. Stahelin HF, von Wartburg A (1991) The chemical and biological route from podophyllotoxin glucoside to etoposide: Ninth Cain memorial award lecture. Cancer Res 51:5-15
3. Cain BF, Atwell GJ (1974) The experimental antitumour properties of three congeners of the acridylmethanesulphonanilide (AMSA) series. Eur J Cancer Clin Oncol 10:539-549
4. Arlin ZA, Sklaroff RB, Gee TS, Kempin SJ, Howard J, Clarkson BD, Young CW (1980) Phase I and II trial of 4'-(9-acridinylamino) methanesulfon-m-anisidide in patients with acute leukemia. Cancer Res 40:3304-3306
5. Baguley BC, Denny WA, Atwell GJ, Finlay GJ, Rewcastle GW, Twigden SJ, Wilson WR (1984) Synthesis, antitumor activity, and DNA binding properties of a new derivative of amsacrine, N-5-dimethyl-9-[(2-methoxy-4-methylsulfonylamino) phenylamino]-4-acridinecarboxamide. Cancer Res 44:3245-3251
6. Harvey VJ, Hardy JR, Smith S, Grove W, Baguley BC (1991) Phase II study of the amsacrine analogue CI-921 (NSC 343499) in non-small cell lung cancer. Eur J Cancer 27:1617-1620
7. McCrystal MR, Evans BD, Harvey VJ, Thompson PI, Porter DJ, Baguley BC (1999) Phase I study of the cytotoxic agent N-[2-(dimethylamino) ethyl]acridine-4-carboxamide. Cancer Chemother Pharmacol 44:39-44
8. Baguley BC, Zhuang L, Marshall E (1995) Experimental solid tumour activity of N-[2-(dimethylamino) ethyl]-acridine-4-carboxamide. Cancer Chemother Pharmacol 36:244-248
9. Deady LW, Rodemann T, Zhuang L, Baguley BC, Denny WA (2003) Synthesis and cytotoxic activity of carboxamide derivatives of benzo[b][1, 6]naphthyridines. J Med Chem 46:1049-1054
10. Deady LW, Rogers ML, Zhuang L, Baguley BC, Denny WA (2005) Synthesis and cytotoxic activity of carboxamide derivatives of benzo [b][1, 6]naphthyridin-(5H) ones. Bioorg Med Chem 13:1341-1355
11. Lukka PB, Paxton JW, Kestell P, Baguley BC (2010) Pharmacokinetics and distribution of SN 28049, a novel DNA binding anticancer agent, in mice. Cancer Chemother Pharmacol 65:1145-1152
12. Bridewell DJ, Porter AC, Finlay GJ, Baguley BC (2008) The role of topoisomerases and RNA transcription in the action of the antitumour benzonaphthyridine derivative SN 28049. Cancer Chemother Pharmacol 62:753-762
13. Finlay GJ, Baguley BC, Snow K, Judd W (1990) Multiple patterns of resistance of human leukemia cell sublines to amsacrine analogues. J Natl Cancer Inst 82:662-667
14. Marshall ES, Matthews JH, Shaw JH, Nixon J, Tumewu P, Finlay GJ, Holdaway KM, Baguley BC (1994) Radiosensitivity of new and established human melanoma cell lines: comparison of [3H] thymidine incorporation and soft agar clonogenic assays. Eur J Cancer 30 A: 1370-1376
15. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, Sedivy JM, Kinzler KW, Vogelstein B (1998) Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282:1497-1501
16. Parmar J, Marshall ES, Charters GA, Holdaway KM, Shelling AN, Baguley BC (2000) Radiation-induced cell cycle delays and p53 status of early passage melanoma cell lines. Oncol Res 12:149-155
17. Deady LW, Kaye AJ, Finlay GJ, Baguley BC, Denny WA (1997) Synthesis and antitumor properties of N-[2-(dimethylamino) ethyl] carboxamide derivatives of fused tetracyclic quinolines and quinoxalines: a new class of putative topoisomerase inhibitors. J Med Chem 40:2040-2046
18. Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM (1998) DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 273:5858-5868
19. Tanaka T, Huang X, Halicka HD, Zhao H, Traganos F, Albino AP, Dai W, Darzynkiewicz Z (2007) Cytometry of ATM activation and histone H2AX phosphorylation to estimate extent of DNA damage induced by exogenous agents. Cytometry A 71:648-661
20. Bridewell DJA, Finlay GJ, Baguley BC (1999) Mechanism of cytotoxicity of N-[2-(dimethylamino) ethyl]acridine-4-carboxamide and of its 7-chloro derivative: the roles of topoisomerases I and II. Cancer Chemother Pharmacol 43:302-308
21. Shagisultanova EI, Piao Z, Li HR, Malkhosyan SR (2004) Topoisomerase II gene mutations in tumors and tumor cell lines with microsatellite instability. Cancer Lett 216:221-226
22. Takemura H, Rao VA, Sordet O, Furuta T, Miao ZH, Meng L, Zhang H, Pommier YA (2006) Defective Mre11-dependent activation of Chk2 by ataxia telangiectasia mutated in colorectal carcinoma cells in response to replication-dependent DNA double strand breaks. J Biol Chem 281:30814-30823
23. van Leuken R, Clijsters L, Wolthuis R (2008) To cell cycle, swing the APC/C. Biochim Biophys Acta 1786:49-59
24. Vong QP, Cao K, Li HY, Iglesias PA, Zheng Y (2005) Chromosome alignment and segregation regulated by ubiquitination of survivin. Science 310:1499-1504
25. Lanni JS, Jacks T (1998) Characterization of the p53-dependent postmitotic checkpoint following spindle disruption. Mol Cell Biol 18:1055-1064
26. Okada H, Mak TW (2004) Pathways of apoptotic and nonapoptotic death in tumour cells. Nat Rev Cancer 4:592-603
27. Tritarelli A, Oricchio E, Ciciarello M, Mangiacasale R, Palena A, Lavia P, Soddu S, Cundari E (2004) p53 localization at centrosomes during mitosis and postmitotic checkpoint are ATM-dependent and require serine 15 phosphorylation. Mol Biol Cell 15:3751-3757
28. Vogel C, Kienitz A, Hofmann I, Muller R, Bastians H (2004) Crosstalk of the mitotic spindle assembly checkpoint with p53 to prevent polyploidy. Oncogene 23:6845-6853
29. Demidenko ZN, Kalurupalle S, Hanko C, Lim CU, Broude E, Blagosklonny MV (2008) Mechanism of G1-like arrest by low concentrations of paclitaxel: next cell cycle p53-dependent arrest with sub G1 DNA content mediated by prolonged mitosis. Oncogene 27:4402-4410
30. Hoffman WH, Biade S, Zilfou JT, Chen J, Murphy M (2002) Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem 277:3247-3257
31. Luo K, Yuan J, Chen J, Lou Z (2009) Topoisomerase IIalpha controls the decatenation checkpoint. Nat Cell Biol 11:204-210
32. Coelho PA, Queiroz-Machado J, Carmo AM, Moutinho-Pereira S, Maiato H, Sunkel CE (2008) Dual role of topoisomerase II in centromere resolution and aurora B activity. PLoS Biol 6:e207